

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/596,202	06/02/2006	Johannes Bartholomaus	512100-2056	3372
20999 FROMMER I	7590 01/31/2011 AWRENCE & HAUG	EXAMINER		
745 FIFTH AV	VENUE- 10TH FL.		SULLIVAN, DANIELLE D	
NEW YORK, NY 10151			ART UNIT	PAPER NUMBER
			1617	
			MAIL DATE	DELIVERY MODE
			01/31/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/596,202	BARTHOLOMAUS ET AL.	
Examiner	Art Unit	
DANIELLE SULLIVAN	1617	

	DANIELLE SULLIVAIN	1017	
The MAILING DATE of this communication appe	ars on the cover sheet with the o	orrespondence add	ress
THE REPLY FILED 14 January 2011 FAILS TO PLACE THIS A	PPLICATION IN CONDITION FOR	R ALLOWANCE.	
 The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following i application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods: 	the same day as filing a Notice of A replies: (1) an amendment, affidavil eal (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
The period for reply expires months from the mailing	date of the final rejection.		
 The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire to 	ter than SIX MONTHS from the mailing	date of the final rejection	on.
Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(FIRST REPLY WAS FI	LED WITHIN TWO
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filled is the date for purposes of determining the period of ext under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set for	on which the petition under 37 CFR 1.1: ension and the corresponding amount of hortened statutory period for reply origin	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as
may reduce any earned patent term adjustment. See 37 CFR 1.704(b).	y		,
NOTICE OF APPEAL			
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi 	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
<u>AMENDMENTS</u>			
 The proposed amendment(s) filed after a final rejection, to (a) They raise new issues that would require further core (b) They raise the issue of new matter (see NOTE belowed). 	nsideration and/or search (see NOT		cause
(c) They are not deemed to place the application in bett appeal; and/or		ducing or simplifying the	ne issues for
(d) They present additional claims without canceling a c	corresponding number of finally reje	ected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.12	N. Con attack and blassing of blass Con		DTOL 2043
Applicant's reply has overcome the following rejection(s):		ripliant Amendment (F 10L-324).
Newly proposed or amended claim(s) would be all non-allowable claim(s).		imely filed amendmer	nt canceling the
 For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is provided. 		be entered and an e	xplanation of
The status of the claim(s) is (or will be) as follows: Claim(s) allowed:			
Claim(s) objected to:			
Claim(s) rejected: <u>1-14</u> .			
Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE			
8. The affidavit or other evidence filed after a final action, but	t hefore or on the date of filing a No	tice of Anneal will not	he entered
because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).			
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appear and was not earlier presented. Se	and/or appellant fail: ee 37 CFR 41.33(d)(1	s to provide a).
 The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER 	of the status of the claims after er	ntry is below or attach	ed.
The request for reconsideration has been considered but See Continuation Sheet.	t does NOT place the application in	condition for allowan	ce because:
12. Note the attached Information Disclosure Statement(s).	PTO/SB/08) Paper No(s)		
13. Other:			
/Fereydoun G Sajjadi/			

Continuation of 11, does NOT place the application in condition for allowance because: The Examiner maintains the rejection of claims 1-14 under 103(a) over Nara et al. (US, 245, 351) and Rupprecht et al. (DE 10146251) for reasons of record. Applicant's arguments have been fully considered but are not found persuasive. First, Applicant argues that Stover case law that the facts do not resemble the instant invention because it would be nonsequencial to place the active ingredient in a film which coats Nara's core as this film is destroyed in providing the enteric effect. The Examiner disagrees with this argument because both Nara and Rupprecht are analogus and relate to method of making drug delivery devices and only differ in the why the active ingredients are dispersed within the process. Since, Rupprecht et al. teaches that the simultaneously spraying step provide uniform distributions of the components there is motivation to utilize the step in formulating drug films where the desired route of delivery is a sheet. Further, Applicant's argue that Nara and Rupprecht references did not appear to be considered as a whole. First, applicant's argue hydrophillic polymers are crosslinked by polyacrylic acid in situ which is not met by Nara. The Examiner is not persuaded by this argument because Nara teaches in Example 7 hydrophilic polymer. hydroxyproplycellulose is spray coated with a crosslinked polyacrylic polymer which would inheritly crosslink in situ. Further, Applicant argues there is no mention of simultaneous spraying. The Examiner is not persuaded by this argument because because it is the combination of Nara and Rupprect that is utilized to overcome the teachings of the prior art, not Nara alone and Applicant is seeking to perform a piecemeal analysis where the claims have been rejected based on a combination of refereces. Rupprecht et al teach formulating drugs in the form of a film where the solution are sprayed simultaneously was known at the time of invention and one would have been motivated to utilize the spraying device to formulation the present invention to form uniform distribution of the film-formed components.